All In Biotech

Drug Trial Radar · NCT03349060

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND OLDER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Last checked: Nov 19, 2026Latest source record: Dec 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 387 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

387

Actual

Start

Dec 7, 2017

Primary completion

Mar 26, 2019

Study completion Mar 26, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. The efficacy and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated relative to placebo over 12 weeks of study participation. Eligible patients will have an option to enter a long-term extension study after completing 12 weeks of treatment.

Conditions

  • Dermatitis, Atopic

Interventions

  • PF-04965842 100 mgDrug

    PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks

  • PF-04965842 200 mgDrug

    PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks

  • PlaceboDrug

    Placebo, administered as two tablets to be taken orally once daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12Time frame: Baseline, Week 12
  2. Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response of >=75 Percent (%) Improvement From Baseline at Week 12Time frame: Baseline, Week 12

Locations

88 sites in 8 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama, LLC

    Birmingham, Alabama

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • Rady Children's Hospital - San Diego/University of California, San Diego

    San Diego, California

  • TCR Medical Corporation

    San Diego, California

  • Clinical Science Institute

    Santa Monica, California

  • Florida Academic Centers Research and Education, LLC

    Coral Gables, Florida

  • Olympian Clinical Research

    Largo, Florida

  • Forward Clinical Trials, Inc.

    Tampa, Florida

  • Meridian Clinical Research, LLC

    Savannah, Georgia

  • NorthShore University HealthSystem Dermatology Clinical Trials Unit

    Skokie, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Dawes Fretzin Dermatology Group, LLC

    Indianapolis, Indiana

  • Tufts Medical Center

    Boston, Massachusetts

  • Henry Ford Medical Center, New Center One

    Detroit, Michigan

  • Somerset Skin Centre

    Troy, Michigan

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Vital Prospects Clinical Research Institute, P.C.

    Tulsa, Oklahoma

  • Oregon Health & Science University

    Portland, Oregon

  • Medical University of South Carolina Investigational Drug Services

    Charleston, South Carolina

  • MUSC SCTR Research Nexus Clinic and Laboratory

    Charleston, South Carolina

  • Arlington Research Center, Inc.

    Arlington, Texas

  • The University of Texas Health Science Center Houston

    Houston, Texas

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas

  • Virginia Clinical Research, Inc.

    Norfolk, Virginia

  • Pace Dermatology Associates

    Lakewood, Washington

  • MultiCare Allenmore Hospital

    Tacoma, Washington

  • MultiCare Institute for Research and Innovation

    Tacoma, Washington

  • Pace Dermatology Associates

    Tacoma, Washington

  • Australian Clinical Research Network (ACRN)

    Maroubra, New South Wales, Australia

  • Spectrum Medical Imaging

    Maroubra, New South Wales, Australia

  • Queensland X-Ray

    Upper Mount Gravatt, Queensland, Australia

  • Veracity Clinical Research Pty Ltd

    Woolloongabba, Queensland, Australia

  • Emeritus Research

    Camberwell, Victoria, Australia

  • Skin and Cancer Foundation Inc

    Carlton, Victoria, Australia

  • Melbourne Radiology Clinic

    East Melbourne, Victoria, Australia

  • Sinclair Dermatology

    East Melbourne, Victoria, Australia

  • The Royal Children's Hospital

    Parkville, Victoria, Australia

  • Bridge Road Imaging

    Richmond, Victoria, Australia

  • Kirk Barber Research

    Calgary, Alberta, Canada

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.